is a China-based startup in the Biopharma and Biotechnology industries, founded in 2021. The company focuses on utilizing induced pluripotent stem cells (iPSCs) and advanced technologies including gene editing and algorithm-driven cellular differentiation to revolutionize tumor immunotherapy and regenerative medicine. iCamuno centers its approach on being "demand-oriented, patient-centered," with the goal of providing universal, effective, and affordable cell therapies. The latest milestone for iCamuno came on 28 August 2023 with a significant CNY100.00M Series A investment. The investment was led by Delian Capital, along with participation from Zhiyi Investment and West Lake Science and Technology Direct Investment Fund. This injection of capital is expected to further propel iCamuno in advancing its cutting-edge technologies and expanding its impact within the biopharma and biotechnology sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | CNY100.00M | 3 |
|
28 Aug 2023 |
| Series A | CNY200.00M | - | 31 Mar 2022 | |
| Series A | CNY100.00M | - | 01 Sep 2021 | |
| Seed Round | Unknown | - | 01 Apr 2021 |
No recent news or press coverage available for iCamuno Biotherapeutics Pty Ltd.
We care about your data, and we'd love to use cookies make your experience better.